Orchestra BioMed Holdings (OBIO) Share-based Compensation (2022 - 2026)
Orchestra BioMed Holdings' (OBIO) quarterly Share-based Compensation came in at $11.0 million in Q1 2026, up 270.99% year-on-year from $3.0 million in Q1 2025, and up 2250.43% on a QoQ basis from $468000.0 in Q4 2025.
Orchestra BioMed Holdings (OBIO) Share-based Compensation (2022 - 2026) Analysis & Trends
Orchestra BioMed Holdings (OBIO) has 5 years of Share-based Compensation data on file, last reported at $11.0 million in Q1 2026.
- On a quarterly basis, Share-based Compensation rose 270.99% year-over-year to $11.0 million in Q1 2026; TTM through Mar 2026 was $11.0 million, a 104.31% increase from a year earlier, with the FY2025 full-year figure at $6.6 million, down 10.81% from the prior year.
- Share-based Compensation for Q1 2026 stood at $11.0 million, up from $468000.0 in the prior quarter.
- Over the last five years, Share-based Compensation for OBIO reached as high as $11.0 million in Q1 2026 and fell as low as -$313000.0 in Q4 2024.
- Historically, Share-based Compensation has averaged $2.6 million across 5 years, with a median of $919000.0 in 2023.
- Across the five-year window, Share-based Compensation plunged 134.06% in 2024 and surged 5663.89% in 2025, its largest moves.
- Year by year, Share-based Compensation stood at $863000.0 in 2022, then gained by 6.49% to $919000.0 in 2023, then plunged by 134.06% to -$313000.0 in 2024, then surged by 249.52% to $468000.0 in 2025, then soared by 2250.43% to $11.0 million in 2026.
- Per Business Quant data, the three most recent Share-based Compensation figures were $11.0 million in Q1 2026, $468000.0 in Q4 2025, and $359000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 9.26 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.18 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 87.30 Mn |
| 10 | Orchestra BioMed Holdings | 228.31 Mn | 143.68 Mn | 78,000.00 | 11.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.00 Mn |
| Mar 31, 2026 | 11.00 Mn |
| Dec 31, 2025 | 468,000.00 |
| Dec 31, 2025 | 468,000.00 |
| Sep 30, 2025 | 359,000.00 |
| Sep 30, 2025 | 359,000.00 |
| Jun 30, 2025 | 8.30 Mn |
| Jun 30, 2025 | 8.30 Mn |
| Mar 31, 2025 | 2.97 Mn |
| Mar 31, 2025 | 2.97 Mn |
| Dec 31, 2024 | -313,000.00 |
| Dec 31, 2024 | -313,000.00 |
| Sep 30, 2024 | 10.70 Mn |
| Sep 30, 2024 | 10.70 Mn |
| Jun 30, 2024 | 144,000.00 |
| Jun 30, 2024 | 144,000.00 |
| Mar 31, 2024 | 2.59 Mn |
| Mar 31, 2024 | 2.59 Mn |
| Dec 31, 2023 | 919,000.00 |
| Dec 31, 2023 | 919,000.00 |